CHUGAI-PHARMACEUTICAL
14.3.2019 07:02:06 CET | Business Wire | Press release
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra® (emicizumab) , a hemophilia A treatment originated by Chugai, has EU marketing authorization for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors. The EU Commission also approved that Hemlibra can be used with multiple dosing options (once weekly, every two weeks, or every four weeks) for all indicated people with hemophilia A, including those with factor VIII inhibitors.
“We are very thrilled that people with severe hemophilia A without inhibitors in the EU can be offered Hemlibra with multiple dosing options,” said Chugai’s President & CEO, Tatsuro Kosaka. “In addition to its efficacy, the availability of subcutaneous injection has been well accepted especially among children. This approval enables flexibility in Hemlibra’s dosing schedule that may better fit into the life of each person with hemophilia A regardless of their inhibitor status. We truly hope that Hemlibra will be widely recognized as a treatment option for hemophilia A, and bring benefits to people with hemophilia A and their caregivers in Europe.”
This approval is based on the results from two Phase III studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of Hemlibra subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of Hemlibra subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.
In Japan, Chugai obtained regulatory approval for Hemlibra from the Ministry of Health, Labour and Welfare in December 2018 for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.
Notes
Chugai’s HEMLIBRA®
Subcutaneous Injection Receives Approval
for Hemophilia A without Inhibitors and Extension of Dosing Interval
Press
release issued on December 21, 2018
https://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html
About Severe Hemophilia A
People with severe hemophilia A is defined as the condition with less than 1% of factor VIII levels1 . Approximately 50-60% of people with hemophilia A worldwide are expected to have a severe form of the disorder2 .
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
Additional information is
available on the internet at https://www.chugai-pharm.co.jp/english
.
Trademarks used or mentioned in this release are protected by law.
Reference
1) World Federation of Hemophilia : Report on the Annual Global Survey
2017.
2) Marder VJ, et al. Hemostasis and Thrombosis. Basic
Principles and Clinical Practice. 6th Edition, 2013. Milwakee,
Wisconsin. Lippincott Williams and Wilkin.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005942/en/
Contact:
For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp
For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com
For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu
For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw
For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Robotics Partners with NVIDIA to Deliver Industrial-Grade Physical AI at Scale9.3.2026 13:00:00 CET | Press release
ABB Robotics integrates NVIDIA Omniverse libraries into RobotStudio® to deliver physical AI for industry, closing the gap from virtual training to real-world deployment with up to 99% accuracy New RobotStudio HyperReality, available second half of 2026, will fundamentally change how quickly and reliably manufacturers can scale production, reducing costs by up to 40% and accelerating time-to-market by 50% Full range and breadth of industrial applications, with real-world pilot being conducted by Foxconn in consumer electronics assembly At NVIDIA GTC, the robotic workforce company WORKR will showcase how it’s using the solution to help manufacturers across the U.S. addressing critical labor shortages ABB Robotics announced today it is integrating NVIDIA Omniverse libraries into ABB Robotics’ RobotStudio® to help manufacturers deploy physical AI in real world robotics applications. “Today, using NVIDIA accelerated computing and simulation technologies, we have removed the last barriers to
Allegro DVT Launches DWP300 DeWarp Semiconductor IP9.3.2026 13:00:00 CET | Press release
Allegro DVT, the worldwide leader in Semiconductor Video IPs and Video Compliance Tools announces, the addition of its new DWP300 DeWarp IP to its Zinia Pixel Processing IPs portfolio. This latest innovation further reinforces Allegro DVT’s commitment to delivering comprehensive, high-performance solutions for next-generation imaging and video applications. The new DWP300 DeWarp IP is designed for optimal silicon area and power efficiency while offering flexible geometric transformation in real time. It combines a customizable software driver that generates mesh configurations for a wide range of geometric transformations and a dedicated hardware core capable of executing the geometric transformation in real-time on full video. This hybrid Hardware/Software approach enables precise distortion correction while allowing customers to easily adapt the solution to their specific application requirements. With the rapid growth of applications such as automotive surround view, smart surveilla
Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid9.3.2026 12:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. In its February 4, 2026
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”9.3.2026 10:53:00 CET | Press release
Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Excellence” department of medical technology company Siemens Healthineers to develop “Cerebra“, an advanced AI platform designed to deliver rapid, relevant insights across marketing and sales. The concept proved so successful that “Cerebra” was evolved into an Agent Factory, which now standardises, simplifies, and accelerates the deployment of AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309083025/en/ To support labour-intensive manual research in marketing, and sales, Siemens Healthineers now leverages “Cerebra“, an AI-powered knowledge platform that uses specialised AI agents to consolidate internal and external data. In the fast-moving and highly regulated medical technology market, the ability to analyse information accurately and quickly is
AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue9.3.2026 08:30:00 CET | Press release
Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/ AMINA, 21X and Tokeny partner for end-to-end solution Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom